Vytorin, manufactured by Merck & Co. and Schering-Plough, is a cholesterol-reducing drug touted as effective at treating the two major causes of high choleserol: "food and family." Vytorin contains Zocor, a statin that limits the body's production of cholesterol, with Zetia, a drug that blocks the absorption of cholesterol in the intestines. However, a clinical trial known as the "Enhance Study" showed that Vytorin was no more effective in limiting plaque build-up in the arteries than Zocor alone - which was available as a generic. In August 2009, the drug makers paid $41.5 million to resolve more than 140 Zetia and Vytorin lawsuits that claimed the manufacturers delayed release of the Enhance Study in order to boost profits.